New hope for kids with Crohn's: drug shows promise in small trial
NCT ID NCT01580670
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This study tested a drug called TA-650 (also known as infliximab) in 14 children with moderate to severe Crohn's disease. The drug was given as an IV infusion to reduce inflammation and control symptoms. The goal was to see if it could lower disease activity scores and improve the children's health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC CROHN'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Hokuriku, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kinki, Japan
-
Investigational site
Kyusyu, Japan
-
Investigational site
Tōhoku, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TA-650 (infliximab), a drug that blocks inflammation
What this could lead to
If successful, this could provide a treatment option to control symptoms and improve quality of life for children with Crohn's disease.
What could go wrong
This is a small, completed Phase 3 trial with only 14 participants, so results may not apply to all children. Infliximab can have serious side effects like infections or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.